Completed PHASE2 INTERVENTIONAL 3-arm NCT00605072

The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial (AVEC)

The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial (AVEC Trial)

Sponsor: Hebrew SeniorLife

Conditions Aging Cognitive Impairment Hypertension

Interventions candesartan hydrochlorothiazide lisinopril metoprolol, long-acting nifedipine, long acting

Updated 8 times since 2017 Last updated: Jan 14, 2013 Started: Jan 31, 2008 Primary completion: Dec 31, 2011 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00605072, this PHASE2 trial focuses on Aging and Cognitive Impairment and remains completed. Sponsored by Hebrew SeniorLife, it has been updated 8 times since 2008, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Dec 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hebrew SeniorLife
National Institute on Aging (NIA)
University of Southern California

Data source: University of Southern California

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States
• Los Angeles, United States